Business & Finance

ASCO Guï Fremegen has published highly encouraged data from a phase II clinical trial evaluating ijitamabvedotin as a perioperative regimen for bladder cancer and immunotherapy




ASCO Guï Fremegen has published highly encouraged data from a phase II clinical trial evaluating ijitamabvedotin as a perioperative regimen for bladder cancer and immunotherapy

Leave a Reply

Your email address will not be published. Required fields are marked *